<DOC>
	<DOCNO>NCT01609036</DOCNO>
	<brief_summary>This observational study evaluate safety efficacy MabThera/Rituxan ( rituximab ) previously untreated patient follicular lymphoma . Data collect 3 year</brief_summary>
	<brief_title>An Observational Study MabThera/Rituxan ( Rituximab ) Patients With Follicular Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /=18 year Patients previously untreated follicular lymphoma ( stage IIIIV ) accord approve summary product characteristic ( SPC ) Contraindications MabThera/Rituxan therapy accord approve SPC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>